1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
"HeartShare 2.0: Refining Heart Failure Subtypes and Treatment Targets for Personalized Clinical Trials" is currently closed and not accepting applications.
HeartShare 2. 0: Refining Heart Failure Subtypes and Treatment Targets for Personalized Clinical Trials is sponsored by National Institutes of Health (NIH). This Notice of Funding Opportunity (NOFO) solicits applications for a new Clinical Trial Center (CTC) and up to seven Clinical Centers (CCs) for the HeartShare 2.
0 program. The CTC will coordinate precision clinical trial activities focused on heart failure with preserved ejection fraction (HFpEF), including master protocol development, project management, recruitment oversight, performance milestones, and scientific conduct of trials.
The CCs will recruit and retain heart failure patients and controls, participate in deep phenotyping protocols, longitudinal follow-up, obtaining tissue biopsies, and recruiting patients for future clinical trials. Eligible applicants may submit proposals for either the CTC or CC, but must have different PIs.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - HeartShare 2. 0: Refining Heart Failure Subtypes and Treatment Targets for Personalized Clinical Trials - Clinical Trial Center and Clinical Centers (U01 Clinical Trial Optional) HeartShare 2.
0: Refining Heart Failure Subtypes and Treatment Targets for Personalized Clinical Trials - Clinical Trial Center and Clinical Centers (U01 Clinical Trial Optional) Agency: National Institutes of Health Assistance Listings: 93. 837 -- Cardiovascular Diseases Research Last Updated: May 21, 2026 View version history on Grants.
gov The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for a new Clinical Trial Center (CTC) and up to seven Clinical Centers (CCs) for the HeartShare 2. 0 program.
The CTC will coordinate precision clinical trial activities focused on heart failure with preserved ejection fraction (HFpEF), including master protocol development, project management, recruitment oversight, performance milestones, and scientific conduct of trials. The CCs will recruit and retain heart failure patients and controls. The CCs will participate in all aspects of conducting a deep phenotyping...
protocol and longitudinal follow-up of HFpEF patients; obtaining tissue biopsies; and recruiting patients for future clinical trials. Eligible applicants may submit proposals for either the CTC or CC, but must have different PIs. Each application should include CTC or CC as part of their project title.
Companion NOFO for RFA-HL-27-009 will support a Data Translation Center (DTC) for overall coordination of the HeartShare program.
Federally recognized Native American tribal governments Public and Indian housing authorities City or township governments Special district governments For-profit organizations other than small businesses Public and state institutions of higher education Independent school districts Private institutions of higher education Nonprofits non-higher education with 501(c)(3) Other Native American tribal organizations Nonprofits non-higher education without 501(c)(3) Refer to Section III.
Eligibility Information in the NOFO for additional information on eligibility. Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed. Grantor contact information Division of Cardiovascular Sciences, HeartShare Team nhlbiheartshare@mail. nih.
gov Division of Cardiovascular Sciences, HeartShare Team nhlbiheartshare@mail. nih. gov File name Description Last updated RFA-HL-27-008-Revised-Full-Announcement.
html RFA-HL-27-008-Revised-Full-Announcement. html May 21, 2026 06:13 PM UTC Link to additional information Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity : Your account requires additional identity verification.
According to the current listing, eligibility includes: Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility. Confirm the full requirements in the official notice before applying.
The published deadline was May 21, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
HeartShare 2.0: Refining Heart Failure Subtypes and Treatment Targets for Personalized Clinical Trials is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article